TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02881697

Intervention type: OTHER
Intervention: Adipose tissue sampling

Intervention type: OTHER
Intervention: Adipose tissue sampling
Study: NCT03020030

Intervention type: DRUG
Group type: OTHER
Intervention: CYTARABINE
Description: Standard of Care
Study: NCT02881697

Intervention type: OTHER
Intervention: Adipose tissue sampling
Study: NCT04289363

Intervention type: BEHAVIORAL
Intervention: Clinical program implementation
Description: Using mixed methods and triangulating multiple sources of data collected over the course of parent and ancillary studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED-initiated BUP clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness. Converging provider and patient perspectives and field notes with process measures and intervention outcomes, including proportions screened, treated, and engaged in treatment, will provide explanation to contextualize and better understand feasibility, acceptability, and factors associated with the rate with which the ED-initiated BUP innovation is adopted and how well it is sustained.
Study: NCT03020030

Intervention type: DRUG
Group type: OTHER
Intervention: CYTARABINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: DASATINIB
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: DASATINIB
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: DEXAMETHASONE
Description: Standard of Care
Study: NCT00578175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-Tetra™ (MMRV vaccine 208136)
Description: One subcutaneous injection.
Study: NCT01998763

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 2000 IU per day
Study: NCT03714243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate BBBD
Description: Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
Study: NCT00578175

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad®
Description: One subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: Two intramuscular injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: Two intramuscular injections.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®
Description: Two intramuscular injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar®
Description: One intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar®
Description: One intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar®
Description: One intramuscular injection.
Study: NCT04459117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II.
Study: NCT02425514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervios ChronOs
Description: The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoMax™
Description: The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
Study: NCT04611802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Initial Vaccination Period)
Description: Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)
Description: In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Crossover Vaccination period)
Description: In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
Description: In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Description: In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
Study: NCT00461279

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavior Therapy
Description: Reframing and understanding cognitions of depression

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal Psychotherapy
Description: Established psychotherapy for depression
Study: NCT03846284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50mg
Description: caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg
Description: caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h.
Study: NCT03875352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CHG technique
Description: The CHG technique includes treatment using dressing with chlorhexidine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CHG technique
Description: The CHG technique includes treatment using dressing with chlorhexidine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HMG technique
Description: The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HMG technique
Description: The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.
Study: NCT01378468

Intervention type: OTHER
Intervention: oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)
Description: see Ebinger et al., IJS, 2010
Study: NCT04070612

Intervention type: OTHER
Intervention: Blood sample
Description: A blood sample of 2 times 2 to 5 ml additional maximum

Intervention type: OTHER
Intervention: Blood sample
Description: A blood sample of 2 times 2 to 5 ml additional maximum

Intervention type: OTHER
Intervention: Blood sample
Description: A blood sample of 2 times 2 to 5 ml additional maximum
Study: NCT01229722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Beeper
Description: Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
Study: NCT03635242

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control. no therapeutic program
Description: The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
Study: NCT03020030

Intervention type: DRUG
Group type: OTHER
Intervention: DEXAMETHASONE
Description: Standard of Care
Study: NCT01229722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARemind
Description: ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
Study: NCT02116088

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teacher Coaching
Study: NCT01716780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care
Study: NCT02406105

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgical thalamotomy
Description: Cybernetic microradiosurgery based thalamotomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyberKnife
Study: NCT01481077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Sustained release for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Sustained release for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Sustained release for 12 weeks
Study: NCT01150565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS low dose and LiRIS high dose
Description: Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
Study: NCT03020030

Intervention type: DRUG
Group type: OTHER
Intervention: DEXAMETHASONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: DEXAMETHASONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: DEXAMETHASONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: DEXAMETHASONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: DEXAMETHASONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: ETOPOSIDE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: ETOPOSIDE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: HYDROCORTISONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: HYDROCORTISONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: HYDROCORTISONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: HYDROCORTISONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: HYDROCORTISONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: HYDROCORTISONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: HYDROCORTISONE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: LEUCOVORIN CALCIUM
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: LEUCOVORIN CALCIUM
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: LEUCOVORIN CALCIUM
Description: Standard of Care
Study: NCT03635242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental. Therapeutic program
Description: People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform
Study: NCT02545426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change the dialysate calcium concentration
Description: The dialysate calcium concentration will be changed according to the prior concentration
Study: NCT03020030

Intervention type: DRUG
Group type: OTHER
Intervention: LEUCOVORIN CALCIUM
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: METHOTREXATE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: METHOTREXATE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: METHOTREXATE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: METHOTREXATE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: METHOTREXATE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: METHOTREXATE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: METHOTREXATE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: NELARABINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: NELARABINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Standard of Care
Study: NCT04697199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri Oral Drops
Description: Subgingival delivery of probiotic suspension

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing using hand and ultrasonic instruments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing using hand and ultrasonic instruments
Study: NCT00412555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir [Tamiflu]
Description: 30-75mg po daily for 6 weeks
Study: NCT02500849

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728mR-HSPC Infusion 3 days following busulfan conditioning

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728mR-HSPC Infusion 3 days following busulfan conditioning
Study: NCT02990325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 150mg
Description: ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 50mg
Description: ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 50mg
Description: ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
Study: NCT00422942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg po weekly
Study: NCT01207427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5945 0.1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5945 0.25 mg
Study: NCT01767844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
Study: NCT01767844

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02052180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine (Control)
Description: 15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
Study: NCT01928758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content Cigarettes
Description: Research cigarettes will have gradually reduced nicotine content

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual Nicotine Content Cigarettes
Description: Usual Nicotine Content Cigarettes
Study: NCT01331876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral Therapy
Description: 15 CBT sessions with a psychologist expert in OCD treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral Therapy
Description: 15 CBT sessions with a psychologist expert in OCD treatment
Study: NCT01026558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: Ceftobiprole, 500 mg as single iv infusion over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftobiprole
Description: Ceftobiprole, 500 mg as single iv infusion over 2 hours
Study: NCT02354027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824 metformin
Description: Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin
Study: NCT01378624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies.
Study: NCT04218942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exime is the name of the single use temporary prostatic stent used instead of the Foley catheter
Description: Insertion after instillation of a local lubricant anesthetic gel in the urethra like for Foley insertion. Calibration of the urethral meatus with a 22F Bougie. Insertion of the Bougie until abutment against the posterior wall of the bulbous urethra just below the striated sphincter. Note depth of abutment on the scale of the Bougie. Retrieve the Bougie and glide the device to the same depth until abutment against the posterior wall of the bulbous urethra. At this stage the stent is correctly positioned. Stent release: unlock the Luer connection between pusher tube and stylet . Retrieve pusher tube, stylet and flattener tube.~Control of correct positioning: ask patient to stand up to verify the absence of any urine leak. Ask patient to void immediately to control clear urine output.
Study: NCT05025306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziziphus honey
Description: ziziphus honey obtained form ziziphus spina-christi trees also called sidr tree
Study: NCT02033486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOBI + DBT
Study: NCT01912482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory training
Description: The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ventilatory training
Description: The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
Study: NCT02186145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of metronidazole; nystatin and dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl
Description: Vaginal cream of metronidazole and nystatin
Study: NCT01442766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.